Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Overview
Date Founded

2001

Headquarters

784 Memorial Drive, Cambridge, MA, 02139, USA

Type of Company

Public

Employees (Worldwide)

23

Industries

Biotechnology
Pharmaceuticals

Company Description

Infinity is an innovative drug discovery and development company dedicated to discovering, developing and delivering to patients best-in-class medicines for diseases with significant unmet need. We believe that our small molecule discovery and development capabilities, strategic alliances, team of highly experienced management and scientists, and corporate culture form the basis of our potential long-term competitive advantage in seeking to deliver best-in-class medicines to patients

Website
Executives & Employees

Chair & Chief Executive Officer

President & Treasurer

Vice President, General Counsel & Secretary

Chief Scientific Officer & Senior Vice President

Senior Vice President, Global Affairs

Senior Vice President, Clinical Development

Vice President, Global Medical Affairs

Co-Founder

Subscribe now to see full list of current and former executives
Board of Directors

Chair & Chief Executive Officer at Infinity Pharmaceuticals, Inc.

Former Partner at Venrock Associates

Executive Vice President & Chief Operating Officer at Vertex Pharmaceuticals, Inc.

Chairman at Real Endpoints LLC

Executive Vice President at Optum, Inc.

Co-Founder at Karyopharm Therapeutics, Inc.

Former General Manager at Celera Corp.

Subscribe now to see full list of current and former board members
Paths to Infinity Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Infinity Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Mont Blanc Capital Management AG is a private company headquartered in Zurich,, that provides investment advice. It was founded in 2005 by Jens Biertumpel. Bross Ulrich is currently the CEO of the firm.

Details Hidden

Mont Blanc Capital Management AG is a private company headquartered in Zurich,, that provides investment advice. It was founded in 2005 by Jens Biertumpel. Bross Ulrich is currently the CEO of the firm.

Subscribe now to see full details
Recent Transactions
Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. raised money in a private placement transaction

Subscribe now to see full list of recent transations
Insider Transactions
Details Hidden
Subscribe now to see full details
Transaction Advisors
Legal Advisor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Auditor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Subscribe now to see 5+ more transaction advisors
Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Managing Director

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Subscribe now to see 3+ more transaction advisors
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Subscribe now to see advisors & consultants for over 2.5 million organizations
Clients

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAK, PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Subscribe now to see clients for over 2.5 million organizations
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$100M
Total Enterprise Value
$-6.65M
Earnings Per Share
$-0.61
Revenue
$18.7M
Net Profit
$-30.1M
EBITDA
$-121M
EBITDAMargin
-647.27%
Total Debt
$19.6M
Total Equity
$82.5M
Enterprise Value Sales
-0.36x
TEVNet Income
0.22x
Debt TEV
-2.94x
Five Year Compounded Annual Growth Rate Of Revenue
-27.39%
Subscribe now to see full financial details
Non-Profit Donations & Grants
Subscribe now to see non-profit donations & grants for over 2.5 million organizations
Suppliers
Takeda Pharmaceutical Co., Ltd. Chemicals | Tokyo, TY

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Bristol-Myers Squibb Company Pharmaceuticals | Princeton, NJ

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

AbbVie, Inc. Medical Support Services | North Chicago , IL

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

Subscribe now to see suppliers for over 2.5 million organizations
Competitors
Amgen, Inc. Biotechnology - Wilmington, DE

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer, Inc. engages in the manufacture of vaccines and injectable biologic medicines. It operates through the Pfizer Innovative Health and Pfizer Essential Health segments. The Pfizer Innovative Health segment focuses on developing and commercializing novel, value-creating medicines, and vaccines for the internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and consumer healthcare. The Pfizer Essential Health segment comprises of global brands, sterile injectable pharmaceuticals, infusion systems, biosimilars, and Pfizer CentreOne. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Celgene Corp. Pharmaceuticals - Summit, New Jersey

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies